Foresite Capital and F-Prime Capital led a £35m Series C funding round in Genomics.

Foresite Capital, an American venture capital and growth equity firm, and F-Prime Capital, a global venture capital firm investing in healthcare and technology, led a £35m Series C funding round in Genomics, a pioneering health tech company focusing on polygenic risk scoring, with participation from Infinity Investment Partners and MassMutual. “Our vision is that in 10 to 15 years’ time, genetic information will be ubiquitous in healthcare systems,” Peter Donnelly, Genomics CEO.